SCHEDULE: Iroquois Capital and Affiliates Disclose Significant Stake in BriaCell Therapeutics

Iroquois Capital Management, Richard Abbe, and Kimberly Page have disclosed beneficial ownership of BriaCell Therapeutics Corp. common shares, with Richard Abbe holding a 9.1% stake.

Summary

• Iroquois Capital Management, LLC, Richard Abbe, and Kimberly Page have filed a Schedule 13G disclosing their beneficial ownership in BriaCell Therapeutics Corp.
• Richard Abbe beneficially owns an aggregate of 1,600,000 common shares, representing 9.1% of the class.
• Iroquois Capital Management, LLC and Kimberly Page each beneficially own 560,000 common shares, representing 3.2% of the class.
• The reported percentages are based on 17,551,092 common shares outstanding as of the completion of the offering referenced in the Company's Prospectus (Registration No. 333-288562), filed on July 16, 2025.
• The reporting persons also hold warrants exercisable for an aggregate of 1,633,667 additional common shares (572,000 for IMF and 1,061,667 for ICIG), but these warrants are subject to 4.99% Beneficial Ownership Blockers and are not currently exercisable.
• Richard Abbe has sole voting and dispositive power over 1,040,000 shares and shared voting and dispositive power over 560,000 shares.
• Iroquois Capital Management, LLC and Kimberly Page each have shared voting and dispositive power over 560,000 shares.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or outlook. It simply reports a significant stake by certain investors.

Risks

• Warrants held by the reporting persons are subject to 4.99% Beneficial Ownership Blockers, which currently prevent their exercise and limit the potential increase in the reporting persons' ownership stake.

Future Outlook

NA

Industry Context

This filing reflects a significant institutional and individual investor stake in BriaCell Therapeutics, a company operating in the biotechnology sector. Such disclosures are common for investors accumulating positions in public companies, particularly those in growth-oriented industries like biotech, where strategic investments can signal confidence in future prospects.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding significant ownership stakes by institutional and individual investors, which can influence market perception and trading activity. The presence of beneficial ownership blockers on warrants may limit immediate dilution from warrant exercises.

Key Dates

Keywords

BriaCell Therapeutics, Iroquois Capital Management, Richard Abbe, Kimberly Page, Beneficial Ownership, Schedule 13G, Common Shares, Warrants, Investment Advisor, Biotechnology